Thromb Haemost 2015; 114(05): 1058-1063
DOI: 10.1160/TH15-01-0066
New Technologies, Diagnostic Tools and Drugs
Schattauer GmbH

The value of the thromboelastometry heparinase assay (HEPTEM) in cardiac surgery

Michael Isaäc Meesters
1   Department of Anaesthesiology, Institute for Cardiovascular Research (ICAR), VU University Medical Centre, Amsterdam, the Netherlands
,
Marcus Daniel Lancé
2   Department of Anaesthesiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands
,
Robin van der Steeg
1   Department of Anaesthesiology, Institute for Cardiovascular Research (ICAR), VU University Medical Centre, Amsterdam, the Netherlands
,
Christa Boer
1   Department of Anaesthesiology, Institute for Cardiovascular Research (ICAR), VU University Medical Centre, Amsterdam, the Netherlands
› Author Affiliations
Financial support: This work was supported by the department of Anaesthesiology of the VU University Medical Centre and Maastricht University Medical Centre.
Further Information

Publication History

Received: 22 January 2015

Accepted after major revision: 12 June 2015

Publication Date:
06 December 2017 (online)

Summary

The thromboelastometry INTEM clotting time (CT) with heparinase (HEPTEM) is frequently used to detect residual heparin after cardiopulmonary bypass (CPB) in cardiac surgery. This study investigated whether the HEPTEM CT reflects the presence of residual heparin and the association of the protamine-to-heparin ratio to the INTEM and HEPTEM CT. We retrospectively evaluated thromboelastometry data that were obtained before CPB and after protamine infusion following CPB in two tertiary hospitals. The number of patients with an INTEM:HEPTEM ratio (IH-ratio) > 1, suggesting residual heparin, were quantified. Moreover, the influence of different protamine-to-heparin-dosing-ratios (P:H) on the INTEM and HEPTEM CT was evaluated in the clinical setting and in blood drawn from healthy volunteers. An INTEM:HEPTEM CT ratio > 1.1 was observed in 16% of the patients prior to CPB, and in 15% after protamine administration. Interestingly, 23% and 36% of the patients had an HEPTEM CT exceeding the INTEM CT before CPB and following protamine administration. The HEPTEM CT was longer than the INTEM CT in patients with a P:H-ratio of 1:1 (265 ± 132 vs 260 ± 246 s; p=0.002) or P:H-ratio of 1.3:1 (357 ± 174 vs 292 ± 95 s; p=0.001). Increasing P:H-ratios induced a prolonged HEPTEM CT in fresh blood. In conclusion, limited agreement was observed between INTEM and HEPTEM clotting time in the absence of heparin. INTEM comparison to HEPTEM may not always reliably reflect the presence of residual heparin, while protamine may additionally affect the latter test. These observations complicate HEPTEM results interpretation in clinical situations with suspected residual heparin effect after protamine.

 
  • References

  • 1 Mittermayr M, Margreiter J, Velik-Salchner C. et al. Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem): an in vitro study. Br J Anaesth 2005; 95: 310-316.
  • 2 Hanke AA, Herold U, Dirkmann D. et al. Thromboelastometry Based Early Goal-Directed Coagulation Management Reduces Blood Transfusion Requirements, Adverse Events, and Costs in Acute Type A Aortic Dissection: A Pilot Study. Transfus Med Hemother 2012; 39: 121-128.
  • 3 Karlsson M, Ternstrom L, Hyllner M. et al. Prophylactic Fibrinogen Infusion in Cardiac Surgery Patients: Effects on Biomarkers of Coagulation, Fibrinolysis, and Platelet Function. Clin Appl Thromb Hemost 2011; 17: 396-404.
  • 4 Brenner T, Schmidt K, Delang M. et al. Viscoelastic and aggregometric point-of-care testing in patients with septic shock – cross-links between inflammation and haemostasis. Acta Anaesthesiol Scand 2012; 56: 1277-1290.
  • 5 Carr J, Silverman N. The heparin-protamine interaction. A review. J Cardiovasc Surg 1999; 40: 659-666.
  • 6 Ni Ainle F, Preston RJS, Jenkins PV. et al. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood 2009; 114: 1658-1665.
  • 7 Cobel-Geard R, Hassouna H. Interaction of protamine sulfate with thrombin. Am J Hematol 1983; 14: 227-233.
  • 8 Chu AJ, Wang ZG, Raicu M. et al. Protamine inhibits tissue factor-initiated extrinsic coagulation. Br J Haematol 2001; 115: 392-399.
  • 9 Mochizuki T, Olson PJ, Szlam F. et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998; 87: 781-785.
  • 10 Nielsen VG. Protamine Enhances Fibrinolysis by Decreasing Clot Strength: Role of Tissue Factor-Initiated Thrombin Generation. Ann Thorac Surg 2006; 81: 1720-1727.
  • 11 Bolliger D, Szlam F, Azran M. et al. The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations. Anesth Analg 2010; 111: 601-608.
  • 12 Khan NU, Wayne CK, Barker J. et al. The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph. Eur J Anaesthesiol 2010; 27: 624-627.
  • 13 Gertler R, Wiesner G, Tassani-Prell P. et al. Are the Point-of-Care Diagnostics MULTIPLATE and ROTEM Valid in the Setting of High Concentrations of Heparin and Its Reversal With Protamine?. J Cardiothorac Vasc Anesth 2011; 25: 981-986.
  • 14 Mittermayr M, Velik-Salchner C, Stalzer B. et al. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study. Anesth Analg 2009; 108: 743-750.
  • 15 Vonk ABA, Meesters MI, van Dijk WB. et al. Ten-year patterns in blood product utilization during cardiothoracic surgery with cardiopulmonary bypass in a tertiary hospital. Transfusion 2014; 54: 2608-2616.
  • 16 Lang T, Bauters A, Braun SL. et al. Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis 2005; 16: 301-310.
  • 17 Nagler M, ten Cate H, Kathriner S. et al. Consistency of thromboelastometry analysis under scrutiny: results of a systematic evaluation within and between analysers. Thromb Haemost 2014; 111: 1161-1166.
  • 18 Theusinger OM, Nurnberg J, Asmis LM. et al. Rotation thromboelastometry (ROTEM) stability and reproducibility over time. Eur J Cardiothorac Surg 2010; 37: 677-683.
  • 19 Weber CF, Gorlinger K, Meininger D. et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012; 117: 531-547.
  • 20 Ichikawa J, Kodaka M, Nishiyama K. et al. Reappearance of circulating heparin in whole blood heparin concentration-based management does not correlate with postoperative bleeding after cardiac surgery. J Cardiothorac Vasc Anesth 2014; 28: 1015-1019.
  • 21 Gronchi F, Perret A, Ferrari E. et al. Validation of rotational thromboelastometry during cardiopulmonary bypass. Eur J Anaesthesiol 2014; 31: 68-75.
  • 22 Vonk AB, Veerhoek D, van den Brom CE. et al. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery. J Cardiothorac Vasc Anesth 2014; 28: 235-241.
  • 23 Newsletter ROTEM®. TEM International. October 2012 page 3.